CVS Group reports 5.9% revenue growth for fiscal 2026

CVS Group reported fiscal 2026 revenue of £712.8M (+5.9% y/y), but like-for-like growth of 2.1% missed its 4%–8% medium-term target. Adjusted EBITDA was £141.5M, essentially in line with expectations (£141.6M), with an EBITDA margin of 19.9% (within the 19%–23% range). Net debt excluding leases rose to £199.6M (from £158.3M), though leverage stayed controlled at 1.63x vs a 2.0x ceiling, alongside £11.7M of buybacks completed and £38.3M remaining.

Analysis

CVSGF reads as a capital-allocation story more than a growth story. The market should reward the combination of low leverage, unused credit capacity, and buybacks, but the multiple will stay capped unless the UK core gets back above a mid-single-digit organic growth run-rate; otherwise the equity is just a levered cash compounder with modest re-rating potential. The second-order effect is that management may keep returning cash instead of pushing harder on M&A or capex, which supports EPS but can leave the competitive gap with faster-growing consolidators essentially unchanged.

The main risk is that this becomes a “good enough” update rather than a catalyst: if regulatory scrutiny on veterinary pricing intensifies or same-store growth stalls again, buybacks will not offset an earnings multiple de-rate. Australia is the cleaner upside lever over 6-18 months, but it is not a near-term trading catalyst unless the mix shift meaningfully accelerates. For the Google AI-spend read-through, the beneficiaries are the infrastructure suppliers, not necessarily the buyer; more capex is strategically positive for share defense, but near-term free-cash-flow optics can still compress the multiple.

Contrarian view: the market may be underestimating how much buybacks can matter for a low-growth, cash-generative name in a higher-rate regime, while overestimating the durability of an organic growth recovery without better end-demand evidence. On Google, consensus may be too focused on capex as a cost and not enough on signaling that management is willing to spend to protect its platform moat; however, the cleaner expression is via the semiconductor/networking stack rather than chasing the parent after a spending uptick.

Key Decisions for Investors

• CVSGF: accumulate only on weakness for a 3-6 month hold; treat it as a cash-return compounder, with upside limited unless UK like-for-like growth re-accelerates above 3%-4%.
• Prefer a thematic long in AI infrastructure suppliers such as NVDA or ANET versus long GOOGL for the next 1-2 quarters; Google’s heavier AI capex is more directly monetized by the supply chain than by immediate parent-level earnings multiple expansion.
• Set a risk alert on CVSGF leverage moving above 1.8x net debt/EBITDA or any slowdown in the buyback pace; either would likely trigger a 10%+ de-rating as the market questions the capital-return thesis.
• If holding CVSGF, hedge with a small short against a UK consumer/services proxy or simply keep size modest; the stock’s upside is mostly earnings-per-share math, while the downside is regulatory or same-store-growth disappointment.